D R Gandara

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
  2. doi A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
    David R Gandara
    Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California Electronic address
    J Thorac Oncol . 2016
  3. pmc Squamous cell lung cancer: from tumor genomics to cancer therapeutics
    David R Gandara
    Davis Comprehensive Cancer Center, University of California, Sacramento, California
    Clin Cancer Res 21:2236-43. 2015
  4. pmc Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform
    David R Gandara
    University of California, Davis Comprehensive Cancer Center, Sacramento, CA Electronic address
    Clin Lung Cancer 16:165-72. 2015
  5. pmc Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications
    David R Gandara
    Division of Hematology and Oncology, University of California, Davis, Sacramento, CA Electronic address
    Clin Lung Cancer 15:1-6. 2014
  6. ncbi Gemcitabine/carboplatin combination regimens: importance of dose schedule
    D R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    Oncology (Williston Park) 14:26-30. 2000
  7. ncbi Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition
    David R Gandara
    University of California Davis Cancer Center, Sacramento, California, USA
    Clin Cancer Res 10:4205s-4209s. 2004
  8. ncbi Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
    David Gandara
    Department of Internal Medicine, Division of Hematology Oncology and Department of Radiation Oncology, UC Davis Cancer Center, University of California Davis Medical Center, 4501 X Street, Sacramento, CA 95817, USA
    Clin Cancer Res 11:5057s-5062s. 2005
  9. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
  10. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006

Detail Information

Publications140 found, 100 shown here

  1. ncbi Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
    ....
  2. doi A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
    David R Gandara
    Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California Electronic address
    J Thorac Oncol . 2016
    ..Part 2, reported herein, evaluated the safety, tolerability, pharmacokinetics, and efficacy of trametinib combinations in patients with NSCLC with and without KRAS mutations...
  3. pmc Squamous cell lung cancer: from tumor genomics to cancer therapeutics
    David R Gandara
    Davis Comprehensive Cancer Center, University of California, Sacramento, California
    Clin Cancer Res 21:2236-43. 2015
    ....
  4. pmc Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform
    David R Gandara
    University of California, Davis Comprehensive Cancer Center, Sacramento, CA Electronic address
    Clin Lung Cancer 16:165-72. 2015
    ..This approach should facilitate derivation of new therapeutic strategies and the transition to individualized therapy. ..
  5. pmc Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications
    David R Gandara
    Division of Hematology and Oncology, University of California, Davis, Sacramento, CA Electronic address
    Clin Lung Cancer 15:1-6. 2014
    ..Here we propose an approach to subtyping PD in the setting of acquired resistance as well as subsequent clinical implications. ..
  6. ncbi Gemcitabine/carboplatin combination regimens: importance of dose schedule
    D R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    Oncology (Williston Park) 14:26-30. 2000
    ..This article describes recent clinical trials evaluating gemcitabine plus carboplatin, and the impact of the dosing schedule on the feasibility and tolerability of this combination...
  7. ncbi Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition
    David R Gandara
    University of California Davis Cancer Center, Sacramento, California, USA
    Clin Cancer Res 10:4205s-4209s. 2004
    ..These studies provide a biological rationale for investigating BAC as a model of predictive markers of EGFR inhibition...
  8. ncbi Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
    David Gandara
    Department of Internal Medicine, Division of Hematology Oncology and Department of Radiation Oncology, UC Davis Cancer Center, University of California Davis Medical Center, 4501 X Street, Sacramento, CA 95817, USA
    Clin Cancer Res 11:5057s-5062s. 2005
    ..Here, we describe conceptual issues, preclinical rationale, and ongoing or planned clinical trials incorporating NTAs into current treatment paradigms for unresectable stage III NSCLC...
  9. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
    ..Herein, we review the rationale for a treatment paradigm employing consolidation docetaxel therapy after concurrent chemotherapy/RT and the results of recent clinical trials using this approach...
  10. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006
    ..Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation...
  11. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
    ....
  12. ncbi Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA, USA
    J Thorac Oncol 1:S20-6. 2006
    ....
  13. ncbi Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:S125-7. 2007
    ..We review data regarding adjuvant therapy of stage I NSCLC from clinical trials performed in North America and Europe. Pertinent trials from Japan are discussed elsewhere in this issue...
  14. pmc Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
    David R Gandara
    University of California Davis Cancer Center, 4501 X St, Suite 3017, Sacramento, CA 95817 2229, USA
    J Clin Oncol 27:3540-6. 2009
    ..This common-arm approach facilitates the prospective study of population-related pharmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated...
  15. doi Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer
    David R Gandara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 5:1933-8. 2010
    ..We investigated the relationship of EGFR mutation status and DNA repair capacity, as exemplified by excision repair cross-complementing 1 (ERCC1) gene expression, as a potential explanation for this observation...
  16. pmc Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)
    Angela M Davies
    Department of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:87-92. 2009
    ..This phase II study of bortezomib in combination with gemcitabine/carboplatin was conducted in chemotherapy-naive advanced NSCLC patients to assess efficacy and safety...
  17. ncbi Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    J Clin Oncol 21:2004-10. 2003
    ..Results were compared with those of the predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation...
  18. ncbi Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST)
    N P Campbell
    The University of Chicago, Chicago, IL Memorial Sloan Kettering Cancer Center, New York, NY City of Hope, Duarte, CA University of California, Davis, Sacramento, CA The University of Chicago Medical Center, Chicago, IL
    J Clin Oncol 29:4. 2011
    ..SOR inhibits KIT, VEGFR, PDGFR-β, and BRAF kinases. In preclinical models, SOR has activity against several IM-RES mutations that are resistant to SU (Heinrich. ASCO 2009)...
  19. ncbi Promising new agents in the treatment of non-small cell lung cancer
    M J Edelman
    Division of Hematology and Oncology, University of California, Davis, USA
    Cancer Chemother Pharmacol 37:385-93. 1996
    ..The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed...
  20. ncbi Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel
    M J Edelman
    Cancer Center, University of California Davis, Davis, California, USA
    Cancer 92:146-52. 2001
    ....
  21. ncbi Rash severity and dose in phase I dose escalation cetuximab (C225) trial
    R S Sangha
    University of California Davis Cancer Center, Sacramento, CA British Columbia Cancer Agency, Vancouver, BC, Canada
    J Clin Oncol 26:14573. 2008
    ..C225 efficacy has been correlated with grade of skin rash, which is reported to be dose dependent. This study examined the safety and feasibility of escalating weekly C225 doses, and evaluated skin rash as a surrogate for tumor response...
  22. ncbi Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento 95817, USA
    Cancer Chemother Pharmacol 48:22-8. 2001
    ..In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status...
  23. ncbi Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer
    Angela Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Semin Oncol 29:10-6. 2002
    ....
  24. ncbi Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
    Philip C Mack
    Cancer and Molecular Research Laboratory, Division of Hematology Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Chemother Pharmacol 51:337-48. 2003
    ..UCN-01 has additional effects on cell cycling, including induction of an RB-associated G(1) arrest...
  25. ncbi Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy
    Tatsuo Kimura
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    Ann N Y Acad Sci 1022:55-60. 2004
    ..It was concluded that detection of tumor DNA in plasma is feasible using molecular techniques and that this approach shows promise for monitoring patient response to therapy...
  26. ncbi Developing targeted therapies for lung cancer
    David R Gandara
    University of California, Davis Cancer Center, USA
    Clin Adv Hematol Oncol 1:648-9, 690. 2003
  27. pmc Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222
    Quynh Thu X Le
    Stanford University, Stanford, CA, USA
    J Clin Oncol 27:3014-9. 2009
    ..We report results of the phase II study designed to confirm this result...
  28. ncbi Neoadjuvant therapy for non-small cell lung cancer
    D R Gandara
    Division of Hematology and Oncology, UC Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Anticancer Drugs 12:S5-9. 2001
    ..Preliminary studies have confirmed the feasibility of integrating docetaxel into neoadjuvant treatment strategies and encouraging results have been reported...
  29. ncbi SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4772-81. 2003
    ..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans...
  30. doi Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
    ..Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors with chemotherapy may increase efficacy by overcoming hypothesized antagonism...
  31. pmc Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial
    Przemyslaw Twardowski
    City of Hope Cancer Ctr, Duarte, CA, USA
    Urology 76:923-6. 2010
    ..Evidence has shown that vascular endothelial growth factor is important in the pathophysiology of urothelial cancer...
  32. ncbi Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126
    H West
    Swedish Cancer Institute, Seattle, WA Southwest Oncology Group, Seattle, WA University of Colorado Health Sciences Center, Aurora, CO University of California Davis Cancer Center, Sacramento, CA
    J Clin Oncol 26:8047. 2008
    ..Ann Oncol 2006)...
  33. ncbi Phase I trial of gemcitabine and paclitaxel in advanced solid tumors
    Nelson Lim
    Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA
    Cancer Invest 21:7-13. 2003
    ..We therefore conducted a phase I trial of a 21-day schedule of weekly gemcitabine and paclitaxel to determine the tolerability, maximum tolerated dose (MTD), and preliminary estimates of efficacy of this regimen...
  34. ncbi Population-based maximum tolerated dose of irinotecan and carboplatin
    Carolyn A Wild
    University of California, Davis Cancer Center, Veterans Administration, Northern California Health Care System, Sacramento, California, USA
    Oncology (Williston Park) 17:11-6. 2003
    ..We recommend dose level 1 of irinotecan (200 mg/m2) and carboplatin (AUC 5) for chemotherapynaive patients, and dose level-1 of irinotecan (150 mg/m2) and carboplatin (AUC 5) for chemotherapy-treated patients in phase II trials...
  35. pmc Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
    Paul J Hesketh
    Division of Hematology Oncology, Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts, USA
    J Thorac Oncol 3:1026-31. 2008
    ..Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed...
  36. ncbi Predictive value of EGFR and KRAS mutations detected in plasma from non-small cell lung cancer (NSCLC) patients treated with docetaxel and intermittent erlotinib
    P C Mack
    University of California Davis Cancer Center, Sacramento, CA University of California Davis, Davis, CA
    J Clin Oncol 26:8062. 2008
    ..We used an allele-specific PCR assay to detect EGFR & KRAS mutations in plasma DNA from NSCLC patients (pts) treated with docetaxel and intermittent erlotinib (Davies, ASCO 2007)...
  37. ncbi Phase I trial of combination nab-paclitaxel and pemetrexed in advanced solid tumors
    C Ho
    British Columbia Cancer Agency, Vancouver, BC, Canada University of California Davis Campus, Sacramento, CA
    J Clin Oncol 26:13530. 2008
    ..We hypothesized that the combination of ABI-007 and pemetrexed will have at least an additive anti-tumor effect and will be well-tolerated with manageable side effects...
  38. ncbi Intermittent erlotinib (ERL) in combination with pemetrexed (PEM): Phase I schedules designed to achieve pharmacodynamic separation
    A M Davies
    University of California Davis Cancer Center, Sacramento, CA British Columbia Cancer Agency, Vancouver, BC, Canada University of California Davis, Davis, CA
    J Clin Oncol 26:8032. 2008
    ..Here we report experience with two schedules of intermittent ERL in combination with PEM...
  39. ncbi A phase 0 microdosing trial to identify chemoresistance in bladder cancer
    C Pan
    University of California, Davis, Sacramento, CA Lawrence Livermore National Laboratory, Livermore, CA
    J Clin Oncol 29:264. 2011
    ..By measuring 14C bound to DNA, AMS can detect carboplatin-induced DNA damage after patients receive one subtoxic microdose of 14C-labeled carboplatin...
  40. ncbi Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays
    T Li
    University of California, Davis, Sacramento, CA UC Davis Cancer Center, Sacramento, CA Response Genetics, Inc, Los Angeles, CA University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
    J Clin Oncol 29:10520. 2011
    ....
  41. ncbi Gemcitabine in combination with new platinum compounds: an update
    D R Gandara
    Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    Oncology (Williston Park) 15:13-7. 2001
    ..Here we review recent studies investigating gemcitabine plus carboplatin and preliminary data regarding combinations of gemcitabine with the new platinum analog oxaliplatin...
  42. ncbi Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia
    David R Gandara
    Division of Hematology Oncology and the Department of Radiation Oncology, University of California, Sacramento, CA 95817, USA
    Semin Oncol 29:102-9. 2002
    ..This article reviews the preclinical and clinical development of tirapazamine, as well as current trials in non-small cell lung cancer designed to provide proof of principle for this new category of cancer therapeutics...
  43. ncbi Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Primo N Lara
    Department of Internal Medicine, University of California Davis School of Medicine, UCD Cancer Center, Sacramento 95817, USA
    Semin Oncol 31:40-6. 2004
    ..PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer...
  44. ncbi Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care
    Frederick J Meyers
    Department of Internal Medicine, Cancer Center, The University of California Davis Health System, Sacramento, California 95817, USA
    J Pain Symptom Manage 28:548-56. 2004
    ..SC may enhance coordination of care and facilitate patients' explicit transition from curative intent to palliative intent. In order to validate this approach, a randomized comparative trial evaluating SC has been initiated...
  45. ncbi Natural history of stage I non-small cell lung cancer: implications for early detection
    Dan J Raz
    University of California, San Francisco, 513 Parnassus Ave, S 321, San Francisco, CA 94131, USA
    Chest 132:193-9. 2007
    ..Our hypothesis is that long-term survival in patients with untreated stage I non-small cell lung cancer (NSCLC) is uncommon...
  46. ncbi Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity
    Royce Calhoun
    UC Davis Cancer Center, California, USA
    Oncology (Williston Park) 22:511-6; discussion 516, 521-3. 2008
    ..In addition, the authors consider current treatment options for stage IB NSCLC and review planned clinical trials for stage I disease designed to exploit new pharmacogenomic findings...
  47. ncbi SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung cancer (LSCLC)
    Q Le
    Stanford University, Stanford, CA Southwest Oncology Group Statistical Center, Seattle, WA University of Kansas Medical Center, Kansas City, KS University of California, Davis Cancer Center, Sacramento, CA University of Colorado Health Sciences Center, Aurora, CO Wichita CCOP, Wichita, KS
    J Clin Oncol 26:7523. 2008
    ..A SWOG pilot study (S0004) showed that the combination of TPZ, PE and TRT yielded a promising median survival of 22 months. Here we report results of the phase II study designed to confirm this promising result...
  48. ncbi Phase II trial of 21-day regimen of irinotecan and carboplatin for chemonaive or relapsed small-cell lung cancer: Long-term survival
    G Q Chen
    University of California Davis Cancer Center, Sacramento, CA Kaiser Permanente of Northern California, Vallejo, CA Swedish Institute of Seattle, Seattle, WA Kaiser Permanente of Northern California, Walnut Creek, CA Northern California Veterans Affairs Health System, Sacramento, CA University of California Davis Cancer Center, Sacramento, CA
    J Clin Oncol 26:19009. 2008
    ..We are updating long-term survival data 5 years after initiation of the trial...
  49. ncbi KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536
    P C Mack
    UC Davis Cancer Center, Sacramento, CA Fred Hutchinson Cancer Research Center, Seattle, WA University of Colorado Cancer Center, Aurora, CO M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:8022. 2009
    ..However, in cetuximab-treated NSCLC, a predictive role for KRAS mutations has not been established. We evaluated KRAS status in specimens from two cetuximab-based front-line multicenter SWOG phase II trials in advanced NSCLC...
  50. ncbi Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy: Pilot study results
    D R Gandara
    University of California, Davis, Sacramento, CA Center for Advanced Preclinical Research, National Cancer Institute, Frederick, MD Response Genetics, Inc, Los Angeles, CA The Jackson Laboratory, Sacramento, CA
    J Clin Oncol 29:3053. 2011
    ....
  51. ncbi Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer Invest 21:1-6. 2003
    ..Tamoxifen has been reported to enhance the antitumor activity of cisplatin in preclinical models by modulation of protein kinase C signal transduction and apoptosis-related pathways...
  52. ncbi Docetaxel in non-small cell lung cancer: a review
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Expert Opin Pharmacother 4:553-65. 2003
    ..This paper will review the pharmacology, preclinical, clinical and pharmacoeconomic data supporting the use of docetaxel in the treatment NSCLC...
  53. ncbi Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study
    Primo N Lara
    California Cancer Consortium at the University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4356-62. 2003
    ..We conducted a Phase I study of tirapazamine, carboplatin, and paclitaxel and assessed potential plasma markers of hypoxia as surrogates for response...
  54. ncbi Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved
    Peter F Roberts
    Division of Cardiothoracic Surgery, University California, Davis Medical Center, Sacramento, 95817, USA
    J Thorac Cardiovasc Surg 126:1597-602. 2003
    ..The staging and treatment of multifocal non-small cell cancer are controversial. We evaluated the current staging of multifocal bronchioloalveolar carcinoma and the therapeutic effectiveness of resection when this tumor type is involved...
  55. ncbi Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 5:231-6. 2004
    ..In view of the limited target population for HER2 inhibition, future efforts and resources should be directed toward molecular targets other than HER2 in NSCLC...
  56. ncbi Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 100:2125-31. 2004
    ..The authors screened for HER-2 overexpression in patients developing hormone-refractory prostate carcinoma (HRPC) and conducted a Phase II trial of trastuzumab plus docetaxel in HER-2-positive patients...
  57. ncbi Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 6:102-7. 2004
    ..06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC...
  58. ncbi Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells
    Philip C Mack
    Cancer and Molecular Research Laboratory, Division of Hematology Oncology, Department of Internal Medicine, Sacramento, California 95817, USA
    Radiat Res 162:623-34. 2004
    ..These studies indicate that simultaneous elimination of multiple DNA damage-induced checkpoints in G(1), S and G(2) may enhance the effects of radiation and that drug scheduling may have an impact on clinical efficacy...
  59. ncbi Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Anticancer Drugs 16:317-21. 2005
    ..Three of these prolonged stable disease patients had non-small cell lung cancer. We conclude that intermittent dosing of R115777 is feasible and tolerable. The recommended phase II dose is 600 mg orally b.i.d. on alternate weeks...
  60. ncbi The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 11:4444-50. 2005
    ..Our group has previously shown that UCN-01 potentiates the apoptotic response of agents such as cisplatin in vitro by preventing sequence-specific abrogation of G2 arrest caused by DNA-damaging chemotherapies...
  61. ncbi Bortezomib-based combinations in the treatment of non-small-cell lung cancer
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S59-63. 2005
    ..This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date...
  62. ncbi Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S67-71. 2005
    ..Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way...
  63. ncbi Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 23:9282-9. 2005
    ..We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37...
  64. ncbi A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
    ..Serial serum and urine specimens were collected to assess for markers of bone metabolism...
  65. ncbi Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
    ..Herein we provide the preclinical and clinical rationale for studies examining the concept of pharmacodynamic separation as a means for overcoming hypothesized antagonism of EGFR TKIs and chemotherapy...
  66. ncbi Aurora kinase inhibitors: a new class of targeted drugs in cancer
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:93-8. 2006
    ..This article reviews the biology of aurora kinases, their potential role in the treatment of lung cancer, and challenges in the clinical development of this unique class of antineoplastic agents...
  67. ncbi Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712
    Angela M Davies
    University of California, Davis, Sacramento, CA, USA
    J Clin Oncol 24:5242-6. 2006
    ..This study evaluated adding consolidation paclitaxel after chemoradiotherapy for a similar patient cohort...
  68. ncbi Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma
    Ken Y Yoneda
    Division of Pulmonary Medicine, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
    Clin Lung Cancer 8:S31-5. 2006
    ..The mortality remains high at approximately 30%-50%. We present a review of the incidence, risk factors, clinical manifestations, diagnosis, management, and outcome of this disorder...
  69. ncbi Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
    ..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors...
  70. ncbi Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    J Thorac Oncol 1:996-1001. 2006
    ..We conducted a phase II trial of PS-341 in previously treated patients with platinum-sensitive and -refractory extensive stage SCLC to determine response rate, toxicity, and survival...
  71. ncbi Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer
    Ken Y Yoneda
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California 95817, USA
    J Thorac Oncol 2:537-43. 2007
    ..The primary focus of this blinded review was to determine the incidence of ILD leading to death in 1059 TRIBUTE patients randomized to chemotherapy plus erlotinib or placebo...
  72. ncbi Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
    ..We examined the safety and tolerability of pemetrexed in combination with two different schedules of bortezomib in patients with advanced solid tumors...
  73. doi The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study
    Angela M Davies
    Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA
    J Thorac Oncol 3:68-74. 2008
    ..The combination of gemcitabine and carboplatin is an accepted first-line treatment for advanced NSCLC. We conducted a phase I study of gemcitabine and carboplatin in combination with bortezomib...
  74. ncbi Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
    Christopher M Mahaffey
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:548-53. 2007
    ..We hypothesized that the lack of benefit resulted from a negative interaction between chemotherapy and EGFR TKIs...
  75. doi Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA
    J Clin Oncol 26:463-7. 2008
    ....
  76. pmc The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
    Phillip R Purnell
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:448-54. 2009
    ..This will facilitate the development of tests to identify patients who may benefit from these agents, allow drug activity to be monitored and rationalize the combination of these agents with other treatment modalities...
  77. pmc Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer
    Helen K Chew
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, CA 95817, USA
    J Clin Oncol 27:2163-9. 2009
    ..Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes...
  78. pmc Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 27:2530-5. 2009
    ..To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC...
  79. pmc A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Anticancer Drugs 20:179-84. 2009
    ..Strong preclinical evidence warrants further investigation of AZD0530 in earlier-stage prostate cancer or as combination therapy...
  80. doi Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier
    Randeep Sangha
    University of California, Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Curr Opin Oncol 21:116-23. 2009
    ..Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC...
  81. ncbi Predictive molecular markers: has the time come for routine use in lung cancer?
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California, USA
    J Natl Compr Canc Netw 2:125-31. 2004
    ..To date, none of these markers can be recommended for routine use in clinical practice...
  82. doi Cooperative group research endeavors in small-cell lung cancer: current and future directions
    Randeep Sangha
    Division of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 10:322-30. 2009
    ..Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management...
  83. ncbi Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer
    Tianhong Li
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Curr Drug Targets 11:85-94. 2010
    ..Ongoing research efforts investigating this concept are reviewed...
  84. doi EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 4:1466-72. 2009
    ..We hypothesized that analysis of plasma for EGFR and KRAS mutations from shed tumor DNA would have clinical utility...
  85. pmc Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 116:5710-5. 2010
    ..Because 0124 and 9511 used identical treatment regimens and similar eligibility criteria, patient-level data were pooled from both trials, and a common arm analysis was performed to explore potential reasons for the divergent results...
  86. pmc Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 12:33-7. 2011
    ..A prospective randomized phase II trial of concurrent versus sequential docetaxel and bortezomib was conducted to assess whether administration sequence resulted in measurable clinical differences...
  87. ncbi Non-small-cell lung cancer progression after first-line chemotherapy
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Curr Treat Options Oncol 3:53-8. 2002
    ..In view of the recently established role of docetaxel, ongoing randomized studies are using a common design of single-agent docetaxel versus docetaxel plus a novel investigational agent...
  88. ncbi HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial
    Primo N Lara
    University of California Davis Cancer Center, Division of Hematology Oncology, 4501 X Street, Sacramento, CA 95817, USA
    Cancer 94:2584-9. 2002
    ..The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma...
  89. ncbi Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Philip C Mack
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Lung Cancer 41:S89-96. 2003
    ..PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer...
  90. ncbi Treatment of extensive small cell lung cancer
    Angela M Davies
    University of California Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Hematol Oncol Clin North Am 18:373-85. 2004
  91. ncbi Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:353-6. 2006
  92. ncbi Incorporating bortezomib into the treatment of lung cancer
    Angela M Davies
    UC Davis Cancer Center, University of California, Sacramento, California 95817, USA
    Clin Cancer Res 13:s4647-51. 2007
    ..Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma...
  93. pmc Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, 4501 X St, Ste 3016, Sacramento, CA 95817, USA
    J Clin Oncol 26:4771-6. 2008
    ..We investigated the relationship between clinical outcomes and plasma levels of the hypoxia-associated protein osteopontin (OPN) in patients on this protocol...
  94. ncbi Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): Abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine
    W S Holland
    University of California Davis Cancer Center, Sacramento, CA
    J Clin Oncol 26:16083. 2008
    ..Perifosine, an orally bioavailable AKT inhibitor, has clinical activity against RCC. We sought to determine whether treatment with perifosine and an mTOR-inhibitor (rapamycin) would synergistically inhibit RCC in preclinical models...
  95. ncbi Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors
    R Sangha
    UC Davis Cancer Center, Sacramento, CA BC Cancer Agency, Vancouver, BC, Canada OSI Pharmaceuticals, Boulder, CO
    J Clin Oncol 27:3552. 2009
    ..Given preclinical synergy of C225 and E, we hypothesized this combination would be feasible and result in improved therapeutic benefit...
  96. ncbi BRCA1 mRNA expression patterns in a large lung cancer cohort
    K Kelly
    UC Davis Cancer Center, Sacramento, CA University of California, Davis, Sacramento, CA Response Genetics, Inc, Los Angeles, CA University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
    J Clin Oncol 29:7056. 2011
    ....
  97. ncbi Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen
    P J Hesketh
    Division of Hematology Oncology, St Elizabeth s Medical Center, Boston, MA 02135 2907, USA
    Support Care Cancer 8:46-8. 2000
    ..Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed...
  98. ncbi Positron emission tomography (PET) and improved survival in non-small cell lung cancer (NSCLC) patients: The Will Rogers Phenomenon revisited
    K Chee
    University of California Davis, San Francisco, CA University of California Davis, Sacramento, CA California Cancer Registry, Sacramento, CA
    J Clin Oncol 26:11038. 2008
    ..We investigated whether the use of PET scanning in NSCLC has resulted in this effect...
  99. ncbi Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): A SWOG (S0435) phase II trial
    B J Gitlitz
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA University of Texas M D Anderson Cancer Center, Houston, TX Southwest Oncology Group Statistical Center, Seattle, WA St Louis University, St Louis, MO University of Calfornia Davis School of Medicine, Sacramento, CA
    J Clin Oncol 26:8039. 2008
    ..We conducted a phase II trial of Sorafenib in plat-treated E-SCLC patients (pts) to determine the tumor response rate, toxicity and overall survival...
  100. ncbi Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": Comparative outcomes analysis of JCOG 9511 and SWOG 0124
    P Lara
    University of California Davis Cancer Center, Sacramento, CA SWOG Center for Research and Biostatistics, Seattle, WA Japan Clinical Oncology Group, Tokyo, Japan University of Southern California, Los Angeles, CA Cedars Sinai Medical Center, Los Angeles, CA
    J Clin Oncol 27:8027. 2009
    ....
  101. ncbi Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial
    P Twardowski
    City of Hope Comprehensive Cancer Center, Duarte, CA University of Chicago, Chicago, IL UC Davis Cancer Center, Sacramento, CA University of Pittsburgh Cancer Institute, Pittsburgh, PA Karmanos Cancer Institute, Wayne State University, Detroit, MI University of Southern California, Los Angeles, CA
    J Clin Oncol 27:e16030. 2009
    ..There is evidence that vascular endothelial growth factor (VEGF) is important in the pathophysiology of TCC. Aflibercept is a recombinant fusion protein that binds and neutralizes multiple VEGF isoforms...